Kennedy’s HHS opens path to compounded peptides without FDA approval

What This is

• Health and Human Services (HHS) has published an interim policy stating that it does not intend to take enforcement action against certain pharmacies and physicians that compound six covered peptides under specified conditions.
• HHS chose an enforcement approach—telling the FDA not to act—rather than going through a formal rulemaking process to change compounding rules.
• The policy focuses on peptides such as BPC-157 and TB-500, which are not approved by the FDA and have limited evidence for safety and effectiveness in people.
• Most FDA scientific staff opposed the policy and warned it could weaken the FDA’s role in keeping unproven drugs off the U.S. market.
• FDA scientists and outside experts have warned of potential harms from these injections, including allergic reactions, contamination, organ damage, and unknown long-term risks.
• HHS included safeguards requiring patient-specific prescriptions, ingredient-quality checks, labeling, and safety reporting.
• Compounding pharmacies make customized medications, and their products do not undergo FDA approval before being marketed.
• Use of these peptides has grown through wellness and “medical freedom” circles and social media influencers.
• The policy is temporary while regulators consider whether to formally permit the ingredients in compounding, and HHS says it may reconsider access if safety or product-quality problems emerge.

Why This Matters

• It could reset how much power the FDA uses to block unapproved drugs, by relying more on “we won’t enforce” policies than on clear approvals.
• It may normalize injectable treatments with weak human evidence, shifting risk and uncertainty onto patients and clinicians.
• It sharpens the question of whether “medical freedom” and influencer-driven demand should steer federal health policy.
• It could strain trust inside health agencies if political leaders overrule staff scientists on drug safety standards.